Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Diarrhea | US | 2022

Login to access report north_east
Contact sales account_box

characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three subtypes: constipation 
predominant, diarrhea predominant, and mixed; this analysis focuses on IBS-D, the diarrhea-predominant subtype. Limited treatment options are available for 
IBS, and only a few drugs have secured FDA approval for IBS-D. Current    prescribing among recently treated and newly diagnosed IBS-D patients?
 * How have Viberzi and Lotronex been integrated into the treatment algorithm, and what are their sources of business?
 * What percentage of IBS-D patients receive drug therapy within 365 days
*Markets covered:* United States
*Key companies:* AbbVie, Salix, Sebela Pharmaceuticals
*Key drugs:* Viberzi, Xifaxan, Lotronex, dicyclomine, hyoscyamine sulphate / scopolamine, SSRIs, SNRIs, tricyclic agents, diphenoxylate
 

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
north_east
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…
north_east
Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east